[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

References

• Booth L, Roberts JL, Poklepovic A, Gordon S, Dent P. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget. 2017;8:1449-68. PMID:27903966
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, Dent P. PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget. 2017 Jan 9. doi:10.18632/oncotarget.14562
   Web of Science ®Google Scholar
• Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget. 2016;7:12975-96.
   PubMed Web of Science ®Google Scholar
• Mawatari T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K, Makino I, Nakagawara H, Miyashita T, Tajima H, Takamura H, Fushida S, Ohta T. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol. 2015;47:2073-81.
   PubMed Web of Science ®Google Scholar
• Chen HP, Zhao YT, Zhao TC. Histone deacetylases and mechanisms of regulation of gene expression. Crit Rev Oncog. 2015; 20:35-47. doi:10.1615/CritRevOncog.2015012997. PMID:25746103
   PubMedGoogle Scholar
• Booth L, Roberts JL, Sander C, Lee J, Kirkwood JM, Poklepovic A, Dent P. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017 Jan 27. doi:10.18632/oncotarget.14829
   Web of Science ®Google Scholar
• Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, Mallon CA, Robertson G, Drabick JJ. Malignant melanoma-The cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol. 2016;106:25-54. doi:10.1016/j.critrevonc.2016.04.010. PMID:27637351
   PubMed Web of Science ®Google Scholar
• Beg AA, Gray JE. HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types? Epigenomics. 2016;8:1015-7. doi:10.2217/epi-2016-0066. PMID:27410519
   PubMed Web of Science ®Google Scholar
• Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016;8:705-19. doi:10.2217/imt-2016-0014. PMID:27197539
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, Massengill C, Noyes DR, Martinez GV, Afzal R, Chen Z, Ren X, Antonia SJ, Haura EB, Ruffell B, Beg AA. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2016;22:4119-32. doi:10.1158/1078-0432.CCR-15-2584. PMID:26964571
   PubMed Web of Science ®Google Scholar
• Shen L, Orillion A, Pili R. Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics. 2016;8:415-28. doi:10.2217/epi.15.118. PMID:26950532
   PubMed Web of Science ®Google Scholar
• Yang H, Lan P, Hou Z, Guan Y, Zhang J, Xu W, Tian Z, Zhang C. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.. Br J Cancer. 2015;112:112-21. doi:10.1038/bjc.2014.547. PMID:25393367
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Kirkwood J, Poklepovic A, Dent P. HDAC inhibitors regulate the immunotherapy response of melanoma cells. Oncotarget. 2017: IN PRESS. doi:10.18632/oncotarget.17950
   Web of Science ®Google Scholar
• Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 2009;16:175-83. doi:10.1038/cdd.2008.143. PMID:18846108
   PubMed Web of Science ®Google Scholar
• Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 2010;70:6313-24.
   PubMed Web of Science ®Google Scholar
• Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010;9:2220-31.
   PubMed Web of Science ®Google Scholar
• Tavallai M, Hamed HA, Roberts JL, Cruickshanks N, Chuckalovcak J, Poklepovic A, Booth L, Dent P. Nexavar/Stivarga and viagra interact to kill tumor cells. J Cell Physiol. 2015;230:2281-98.
   PubMed Web of Science ®Google Scholar
• Saddoughi SA, Ogretmen B. Diverse functions of ceramide in cancer cell death and proliferation. Adv Cancer Res. 2013;117:37-58. doi:10.1016/B978-0-12-394274-6.00002-9. PMID:23290776
   PubMed Web of Science ®Google Scholar
• Hoeferlin LA, Fekry B, Ogretmen B, Krupenko SA, Krupenko NI. Folate stress induces apoptosis via p53-dependent de novo ceramide synthesis and up-regulation of ceramide synthase 6. J Biol Chem. 2013;288:12880-90. doi:10.1074/jbc.M113.461798. PMID:23519469
   PubMed Web of Science ®Google Scholar
• Wooten-Blanks LG, Song P, Senkal CE, Ogretmen B. Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. FASEB J. 2007;21:3386-97. doi:10.1096/fj.07-8621com. PMID:17548428
   PubMed Web of Science ®Google Scholar
• Ju R, Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res. 2003;63:2891-7. PMID:12782595
   PubMed Web of Science ®Google Scholar
• Bahr JC, Robey RW, Luchenko V, Basseville A, Chakraborty AR, Kozlowski H, Pauly GT, Patel P, Schneider JP, Gottesman MM, Bates SE. Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget. 2016;7:69804-15. PMID:27634878
   PubMed Web of Science ®Google Scholar
• Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells. Cacan E. Anticancer Res. 2016;36:2819-26.
   Google Scholar
• Hwang JJ, Kim YS, Kim T, Kim MJ, Jeong IG, Lee JH, Choi J, Jang S, Ro S, Kim CS. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest New Drugs. 2012;30:1434-42. doi:10.1007/s10637-011-9718-1. PMID:21773733
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Tavallai M, Webb T, Leon D, Chen J, McGuire WP, Poklepovic A, Dent P. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. 2016;7:19620-30. doi:10.18632/oncotarget.7746. PMID:26934000
   PubMed Web of Science ®Google Scholar